Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

IPO

IPO Calliditas Therapeutics

Read more

Press releases

• Aug 13, 2018Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update
• Aug 6, 2018The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts
• Aug 1, 2018Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry

All press releases

Interim Report Q2 2018

On August 16, 2018, at 07:00am CEST, Calliditas Therapeutics will publish its interim report for the second quarter of 2018.

• Invitation
• Webcast

Read the invitation

Calendar

• Aug 16, 2018Interim report for the period January 1 – June 30, 2018
• Nov 1, 2018Interim report for the period January 1 – September 30, 2018
• Feb 7, 2019Year-end report for the period January 1 – December 31, 2018

All events